News
TKL Research Hires New Vice President of Global Business Development
(Rochelle Park, N.J., June 2, 2015) — TKL Research Inc., a full-service clinical research organization (CRO), is pleased to announce the hiring of Jeffrey Bagshaw as Vice President of Global Business Development for the Clinical Trials Division. Bagshaw will be responsible for leading strategic corporate and business development efforts internationally.
“Jeff is a proven leader in business development and clinical operations,” said Dr. Robert Reardon, Ph.D., Chief Operating Officer at TKL. “This unique combination gives him an exceptional ability to understand client needs and will help us tailor our offerings for rapid enrollment and high-quality clinical research.”
Bagshaw previously served as Chief Operating Officer at Inclinix, Inc., where he was responsible for leading global operations, strategic partnership development and clinical research services. During his tenure at Inclinix, he held various leadership roles in medical marketing and compliance, medical support services and business development.
In addition to Inclinix, Bagshaw has more than 25 years of experience in the pharmaceutical, biotechnology, medical device and applied genomic industries, and he has been responsible for the clinical development and marketing of products across numerous therapeutic areas. His experience includes leadership roles at Hoffmann-La Roche, Bristol-Myers Squibb and Exact Sciences.
Get to know TKL’s leadership team and learn about the company’s capabilities by visiting TKLResearch.com.
About TKL Research, Inc.
Headquartered in Rochelle Park, New Jersey, TKL Research is a full-service international clinical research organization (CRO) serving the pharmaceutical, biotechnology, medical device and consumer healthcare industries. TKL Research provides comprehensive clinical trial management services for Phase I-IV clinical research studies, including an inpatient Phase I facility and outpatient specialized research clinics while delivering to our clients a competitive edge with accelerated enrollment.
###